AnPac Bio-Medical Science Co Ltd
ANPC.OQ- Latest Trade
- trading lower0.27USD
- Change
- -0.01
- % Change
4.97%Negative
- Day Range
- 0.27 - 0.29
- 52-Week Range
- 0.20 - 4.52
As of Jul 2 2022. Values delayed up to 15 minutes
- Previous Close
- 0.29
- Open
- 0.28
- Volume
- 71,015.00
- 3 Month Average Trading Volume
- 22.53
- Shares Out (Mil)
- 19.38
- Market Cap
- 7.26
- Forward P/E
- -99,999.99
- Dividend Yield
- -99,999.99
Key Statistics
mean rating - analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 2.74
- Price To Book (Quarterly)
- 4.57
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 140.03
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -692.79
- Return On Equity (TTM)
- -163.18
2021 (millions USD)
About AnPac Bio-Medical Science Co Ltd
Company Information
AnPac Bio-Medical Science Co., Ltd. is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States.
Address
801 Bixing Street, Bihu CountyLishui, ZHJ
F4 323006
China
Industry
Business Services
Executive Leadership
- Chang Yu
- Co-Chairman of the Board, Co-Chief Executive Officer, Co-Founder
- Aidong Chen
- Co-Chairman of the Board, Co-Chief Executive Officer
- Herbert Yu
- Co-Founder, Chief Medical officer
- Jinqiu Tang
- Chief Financial Officer
- Weidong Dai
- President, China
- Xuedong Du
- Vice President - Research & Development
- Feng Guo
- Director
- Sheng Liu
- Independent Director
- Ren Luo
- Independent Director
- Jianhua Shao
- Independent Director
- Pu Xing
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,806.10 | 0.11%Positive |
| Copper | 679.40 | 2.12%Negative |
| Brent Crude Oil | 111.63 | -- |
| CBOT Soybeans | 1,622.00 | 3.16%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,825.33 | 1.06%Positive |
| Euro STOXX 50 | 3,448.31 | 0.19%Negative |
| FTSE 100 | 7,168.65 | 0.01%Negative |
| Nikkei 225 | 25,935.62 | 1.73%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes